摘要
目的探讨3-羟-3-甲戊二酸A还原酶(HMG-Co A还原酶)抑制剂瑞舒伐他汀与血管紧张素受体拮抗剂(angiotensin receptor blocker,ARB)氯沙坦钾联合应用在长期腹膜透析患者中的作用。方法选择本院72例新腹膜透析患者,随机分为对照组(24例)、氯沙坦组(24例)、联合用药组(24例)。观察期1年,观察3组患者尿量、内生肌酐清除率、血清钾、血压等变化及腹膜平衡实验(peritonealequilibration tests,PET)。通过酶联免疫法(ELISA)检测PET前过夜腹透液中的纤维连接蛋白(fibronectin,FN)、转化生长因子(transforming growth factorβ1,TGF-β1)及患者血清中的C反应蛋白。结果 3组患者肾功能及腹膜功能比较,氯沙坦组优于对照组,联合用药组优于氯沙坦组(P<0.05)。结论长期腹膜透析患者中3-羟-3-甲戊二酸A还原酶(HMG-Co A还原酶)抑制剂联合肾素血管紧张素系统抑制剂可降低超滤量和残余肾功能下降的速度,改善肾功能,抑制腹膜纤维化的发生和发展,在抗腹膜性硬化和保护腹膜功能上起到了积极的作用。
Objective To investigate the effects of both Rosuvastatin Calcium tablets and Losartan Potassium tablets on peritoneal fibrosis in long-term peritoneal dialysis patients. Methods All 72 continous ambulatory peritoneal dialysis were collected in hospital. They were randomly and equally divided into 3 groups（control group,Losartan group,combined group）,each of 24 cases. Their change of urine volume,crea tinine clearance rate, 1-hour peritoneal equilibration test（PET） were observed after 1 year. The fi bronectin,trans forming growth factor β1,C-reactive protein were detected. Results Compared with control group, combined group was significant ly higher than Losartan group about all detection results. Conclusion Both Rosuvastatin Calcium tablets and Losartan Potassium tablets are useful for the prevention and treatment of peritoneal fibrosis.
出处
《中国现代医生》
2015年第8期93-95,共3页
China Modern Doctor
